Professional Documents
Culture Documents
Con base en los genes HLA clase I y clase II con mayor frecuencia se realiz
predicciones de eptopos de clulas T utilizando el mtodo netMHCpan y
netMHCIIpan, programas para MHC I y MHC II respectivamente, disponibles en
los portales http://www.cbs.dtu.dk/services/NetMHCpan/ y
http://www.cbs.dtu.dk/services/NetMHCIIpan/
--------------------------------------------------------------------------------------------------
Seq Allele Core Core_Rel 1-log50k(aff) Affinity(nM) %Rank Exp_Bind BindingLevel
--------------------------------------------------------------------------------------------------
419 DRB1_04:01 FNVVNSSIG 0.810 0.632 53.85 1.20 NA <=SB
361 DRB1_04:01 LKKIQNSLS 0.900 0.624 58.52 1.40 NA <=SB
21 DRB1_04:01 YGSSSNTRV 0.800 0.568 106.75 4.00 NA <=WB
0 DRB1_04:01 KLAILSVSS 0.415 0.559 118.61 4.50 NA <=WB
19 DRB1_04:01 YQCYGSSSN 0.435 0.498 228.09 10.00 NA <=WB
-----------------------------------------------------------------------------------------------------
Seq Allele Core Core_Rel 1-log50k(aff) Affinity(nM) %Rank Exp_Bind BindingLevel
-----------------------------------------------------------------------------------------------------
361 DRB1_01:01 LKKIQNSLS 0.880 0.761 13.34 4.00 NA <=WB
0 DRB1_01:01 LAILSVSSF 0.250 0.752 14.60 5.00 NA <=WB
1 DRB1_01:01 ILSVSSFLF 0.285 0.746 15.62 5.00 NA <=WB
419 DRB1_01:01 FNVVNSSIG 0.780 0.745 15.72 5.50 NA <=WB
--------------------------------------------------------------------------------------------------
Seq Allele Core Core_Rel 1-log50k(aff) Affinity(nM) %Rank Exp_Bind BindingLevel
--------------------------------------------------------------------------------------------------
60 DRB1_03:01 LKKNSRSLG 0.795 0.484 267.12 8.50 NA <=WB
Tabla 5 Eptopos putativos para alelos HLA-A*02:01
-----------------------------------------------------------------------------------
Pos HLA Icore Identity Score %Rank BindLevel
-----------------------------------------------------------------------------------
364 HLA-A*02:01 YLKKIQNSL AAA29554_1_circ 0.5975240 0.3593 <= SB
431 HLA-A*02:01 GLIMVLSFL AAA29554_1_circ 0.3997290 0.7348 <= WB
6 HLA-A*02:01 AILSVSSFL AAA29554_1_circ 0.2630470 1.1679 <= WB
-----------------------------------------------------------------------------------
Pos HLA Icore Identity Score %Rank BindLevel
-----------------------------------------------------------------------------------
356 HLA-A*01:01 PSDKHIEQY AAA29554_1_circ 0.9687060 0.0365 <= SB
15 HLA-A*01:01 FVEALFQEY AAA29554_1_circ 0.9630280 0.0428 <= SB
355 HLA-A*01:01 EPSDKHIEQY AAA29554_1_circ 0.9385480 0.0642 <= SB
354 HLA-A*01:01 EEPSDKHIEQY AAA29554_1_circ 0.8490730 0.1426 <= SB
48 HLA-A*01:01 YNELEMNYY AAA29554_1_circ 0.8186620 0.1634 <= SB
40 HLA-A*01:01 YDNAGTNLY AAA29554_1_circ 0.8011350 0.1750 <= SB
395 HLA-A*01:01 SADKPKDQLDY AAA29554_1_circ 0.7504050 0.2205 <= SB
357 HLA-A*01:01 SDKHIEQY AAA29554_1_circ 0.5609160 0.4132 <= SB
-----------------------------------------------------------------------------------
Pos HLA Icore Identity Score %Rank BindLevel
-----------------------------------------------------------------------------------
47 HLA-A*29:02 LYNELEMNY AAA29554_1_circ 0.9372890 0.0239 <= SB
15 HLA-A*29:02 FVEALFQEY AAA29554_1_circ 0.8586640 0.0867 <= SB
18 HLA-A*29:02 ALFQEYQCY AAA29554_1_circ 0.6686980 0.2483 <= SB
39 HLA-A*29:02 NYDNAGTNLY AAA29554_1_circ 0.6538340 0.2591 <= SB
47 HLA-A*29:02 LYNELEMNYY AAA29554_1_circ 0.6535550 0.2593 <= SB
46 HLA-A*29:02 NLYNELEMNY AAA29554_1_circ 0.6224550 0.2810 <= SB
40 HLA-A*29:02 YDNAGTNLY AAA29554_1_circ 0.6141650 0.2868 <= SB
55 HLA-A*29:02 YYGKQENWY AAA29554_1_circ 0.5808990 0.3145 <= SB
14 HLA-A*29:02 LFVEALFQEY AAA29554_1_circ 0.5361340 0.3597 <= SB
12 HLA-A*29:02 SFLFVEALF AAA29554_1_circ 0.4389800 0.4690 <= SB
54 HLA-A*29:02 NYYGKQENWY AAA29554_1_circ 0.4339990 0.4750 <= SB
-----------------------------------------------------------------------------------
Pos HLA Icore Identity Score %Rank BindLevel
-----------------------------------------------------------------------------------
12 HLA-A*23:01 SFLFVEALF AAA29554_1_circ 0.9241680 0.0569 <= SB
54 HLA-A*23:01 NYYGKQENW AAA29554_1_circ 0.9064240 0.0736 <= SB
53 HLA-A*23:01 MNYYGKQENW AAA29554_1_circ 0.6595740 0.3260 <= SB
7 HLA-A*23:01 ILSVSSFLF AAA29554_1_circ 0.5570340 0.4618 <= SB
Tabla 9 Eptopos putativos para alelos HLA-A*35:01
-----------------------------------------------------------------------------------
Pos HLA Icore Identity Score %Rank BindLevel
-----------------------------------------------------------------------------------
15 HLA-B*35:01 FVEALFQEY AAA29554_1_circ 0.6794300 0.2090 <= SB
355 HLA-B*35:01 EPSDKHIEQY AAA29554_1_circ 0.6745990 0.2132 <= SB
5 HLA-B*35:01 LAILSVSSF AAA29554_1_circ 0.6545310 0.2306 <= SB
330 HLA-B*35:01 MPNDPNRNV AAA29554_1_circ 0.4489830 0.4572 <= SB
EPITOPOS
1. FLFVEALFQE
2. FVEALFQEY
3. LFVEALFQEY
4. SVFNVVNSSI
5. LIMVLSFLF
6. AILSVSSFLF
7. SVSSFLFVEA
8. SFLFVEALF
9. IMVLSFLFL
Segn la informacin recopilada por Sedegah et. al. (2013) las regiones N-
terminal, comprendida de los aminocidos 1 al 104, y la regin C-terminal, de los
aminocidos 273 a 397 son las zonas que presentan una mayor
inmunodominancia para eptopos de clulas T (ilustracin 3), lo que concuerda
con lo registrado por medio de lo recopilado por los programas NetMHCpan y
NetMHCIIpan (ver anexo 1)
Ilustracin 3 Secuencia de aminocidos de Plamosdium falciparum (A), eptopos para MHC II (B), eptopos para MHC I
(C), grupo de eptopos dominantes (D), eptopos confirmados por Elispot (E)
Bibliografa
1. Alvarez G, Pieros JG, Tobn A, Ros A, Maestre A, Blair S, et al. Efficacy
of three choroquine-primaquine regimens for treatment of Plasmodium vivax
malaria in Colombia. Am J Trop Med Hyg. 2006;75:605-9.
2. Ministrio da Sade. Secretaria de Vigilncia em Sade. Aes de Controle
da Malria: manual para profissionais de sade na Ateno Bsica. Braslia,
Ministrio da Sade; 2005.
3. Baragatti M, Fournet F, Henry MC, Assi S, Ouedraogo H, Rogier C, et al.
Social and environmental malaria risk factors in urban areas of
Ouagadougou, Burkina Faso. Malar J. 2009;8:13.
4. UNICEF. El Paludismo. Disponible
en: http://www.unicef.org/spanish/health/index_malaria.html [Consultado: 29
de septiembre de 2017].
5. Sacarlal J, Aide P, Aponte JJ, Renom M, Leach A, Mandomando I, et al.
Long-Term Safety and Efficacy of the RTS.S/AS02A. Malaria Vaccine in
Mozambican Children. J Infect Dis 2009; 200:329-36.
6. Frevert U. Sneaking in through the back entrance: the biology of malaria
liver stages. Trends Parasitol 2004;20(September (9)):41724.
7. Dame JB, Williams JL, McCutchan TF, Weber JL, Wirtz RA, Hockmeyer
WT, et al. Structure of the gene encoding the immunodominant surface
antigen on the sporozoite of the human malaria parasite Plasmodium
falciparum. Science 1984;225(August (4662)):5939.
8. De la Cruz VF, Lal AA, McCutchan TF. Sequence variation in putative
functional domains of the circumsporozoite protein of Plasmodium
falciparum. Implications for vaccine development. J Biol Chem
1987;262(September (25)):119359.
9. Sedegah M, Kim Y, Ganeshan H, Huang J, Belmonte M, Abot E.
Identification of minimal human MHC-restricted CD8+ T-cell epitopes within
the Plasmodium falciparum circumsporozoite protein (CSP). Malaria
Journal,2013,12:185.
10. Alvarez G, Pieros JG, Tobn A, Ros A, Maestre A, Blair S, et al. Efficacy
of three choroquine-primaquine regimens for treatment of Plasmodium vivax
malaria in Colombia. Am J Trop Med Hyg. 2006;75:605-9.
11. Ockenhouse D, Regules J, Tosh D, Cowden J. Ad35.CS.01 - RTS,S/AS01
Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in
Healthy Malaria-Nave Adults. PLoS One. 2015; 10(7): e0131571.
Anexo